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Pyridoxamine, a structural analog of vitamin B6 that exerts antiglycative effects, has been proposed as supplementary approach
in patients with initial diabetic nephropathy. However, the molecular mechanism(s) underlying its protective role has been so far
slightly examined. C57Bl/6J mice were fed with a standard diet (SD) or a diet enriched in fat and fructose (HD) for 12 weeks.
After 3 weeks, two subgroups of SD and HD mice started pyridoxamine supplementation (150mg/kg/day) in the drinking water.
HD fed mice showed increased body weight and impaired glucose tolerance, whereas pyridoxamine administration significantly
improved insulin sensitivity, but not bodyweight, and reduced diet-induced increase in serumcreatinine andurine albumin.Kidney
morphology ofHD fedmice showed strong vacuolar degeneration and loss of tubule brush border, associatedwith a drastic increase
in both advanced glycation end products (AGEs) and AGEs receptor (RAGE). These effects were significantly counteracted by
pyridoxamine, with consequent reduction of the diet-induced overactivation of NF-kB and Rho/ROCK pathways. Overall, the
present study demonstrates for the first time that the administration of the antiglycative compound pyridoxamine can reduce
the early stages of diet-dependent kidney injury and dysfunction by interfering at many levels with the profibrotic signaling and
inflammatory cascades.
1. Introduction
One of the most feared chronic microvascular complications
of diabetes is diabetic nephropathy. In western world, dia-
betes is indeed the leading cause of end-stage renal disease,
surpassing other etiologies, such as hypertension. One-third
of type 1 diabetes mellitus patients and 20% of type 2
diabetes mellitus patients develop end-stage renal disease
[1], a pathological condition that dramatically contributes to
increasing mortality among diabetic patients if compared to
healthy nondiabetic individuals [2].
An early sign of diabetic nephropathy is an increased
protein release in urine, displayed as microalbuminuria,
which is associated with the progression of renal damage,
and is caused by glomerular hypertrophy, hyperfiltration,
widening of basement membranes, tubule-interstitial fibro-
sis, glomerulosclerosis, and podocytopathy [3].
Currently established therapeutic approaches for diabetic
nephropathy are primarily antihypertensives that act on
renin angiotensin aldosterone system, such as angiotensin-
converting enzyme inhibitors and angiotensin II receptor
blockers.These appear to reduce proteinuria and to delay, but
not prevent, the onset of end-stage renal disease [4].
For this reason, one of the most actual challenging
topics is to identify pharmacological treatments that prevent
the onset of diabetic nephropathy by acting on the initial
stages of diabetes related renal dysfunction. One of the most
recently proposed pharmacological tools is pyridoxamine,
a structural analog of vitamin B6 that exerts antiglycative
effect [5]. Pyridoxamine has been demonstrated to be effec-
tive in reducing serum creatinine increase in patients with
initial diabetic nephropathy impairment [4, 6]. Pyridoxamine
solves its action by inhibiting the formation of advanced
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glycation end products (AGEs) from glycated proteins and by
trapping pathogenic reactive carbonyl compounds (Amadori
product), the intermediates in the formation of AGEs [7].
AGEs are irreversible products of protein glycation (glycative
stress) expressed ubiquitously and overproduced in case of
sugar accumulation, such as during hyperglycemia.
We and others have previously contributed to demon-
strating that fructose exposure evokes more AGEs than
glucose, mainly because the anomerization equilibrium for
fructose is shifted more to the reactive, open chain form of
the sugar [8, 9].
Accordingly, accumulation of AGEs (mainly carboxym-
ethyllysine and carboxyethyllysine, CML and CEL) due to
chronic exposure to hypercaloric diets significantly con-
tributes to the progression ofmetabolic, degenerative diseases
and related cardiovascular complications [10–17].
Increasing AGEs levels can cause alterations of extra-
cellular proteins, such as collagen and elastin as well as
the activation, through the interaction with their receptor
RAGE, of different inflammatory signaling pathways in the
kidney. Among these, NF-𝜅B is, indeed, the most influ-
ent inflammatory signal transduction molecule found to
be activated by AGEs-RAGE interaction [18]. Interestingly,
recent findings convincingly show that the activation of the
proinflammatory NF-kB pathway is also involved in the
induction of expression/activity of selective profibrogenetic
signaling pathways [19].
However, so far, the potential beneficial effects of phar-
macological modulation of AGEs production in the con-
text of diet-related kidney dysfunction have been poorly
investigated. To our knowledge, renoprotective effects of
pyridoxamine supplementation have been tested only in
strains of mice genetically programmed to develop diabetic
nephropathy, with limited insights on molecular mecha-
nisms [20–22]. Our study aims to investigate whether oral
administration of pyridoxamine prevents the onset of diet-
related kidney dysfunction, affecting selective inflammatory
and profibrotic signaling pathways in a nongenetic animal
model of diet-induced metabolic disease.
2. Materials and Methods
2.1. Animals and Treatments. Four-week-old male C57Bl/6j
mice (Charles River Laboratories, Calco, Italy) were cared for
in compliance with the EuropeanCouncil directives (number
86/609/EEC) and with the Principles of Laboratory Animal
Care (NIH number 85-23, revised 1985).The scientific project
was approved by the Ethical Committee of the Turin Univer-
sity. Mice were randomly allocated into the following dietary
regimens: standard diet (SD, 𝑛 = 15) and a high-fat high-
fructose diet (HD, 𝑛 = 20) for 12 weeks. Mice were provided
with diet and water ad libitum. The HD contained 45% kcal
fat (soybean oil and lard), 20% protein (casein), and 35%
carbohydrate (fructose) (D03012907 diet, Research Diets).
After three weeks of dietary manipulation, two subgroups
of SD and HD began pyridoxamine supplementation in
the drinking water for the remaining nine weeks (SD +
P, 𝑛 = 5; HD + P, 𝑛 = 10). The pyridoxamine dosage
(1 g/L, the equivalent of about 150mg/kg/day) was chosen
according to literature data [23] and calculated on the average
daily water intake. During the 12 weeks of the experimental
protocol, body weight, glycaemia, and food intake were
strictly monitored.
2.2. Procedures and Plasma Analyses. Six-hour fasting gly-
caemia was measured at the start of the protocol and every
3 weeks by saphenous vein puncture using a conventional
glucometer (GlucoMen LX kit, Menarini Diagnostics). After
12 weeks, mice were anesthetized and euthanized by car-
diac exsanguination. Blood was collected and kidneys were
rapidly removed and transversely sectioned. One-half was
embedded in 4% PAF. The rest of the kidney was frozen
in liquid N2 and stored at −80
∘C for protein analysis.
Plasma lipid profile and creatinine levels were determined
by standard enzymatic procedures using reagent kits. Plasma
insulin and urine albumin level were measured using an
enzyme-linked immunosorbent assay (ELISA) kit.
2.3. Morphological Analysis. Medial sagittal sections of kid-
ney were fixed in 4% formaldehyde solution in M 0.010
phosphate pH7.4 for 18 h at 4∘C.Then, dewaxed 5 𝜇msections
were stained with PAS technique and examined under a light
microscopeOlympus BX41. Ten randomized pictures at×200
were obtained to evaluate the degree of tubular damage.
Accordingly, with previous publication inwhich rodents were
fed with the same diet [24] tubular damage was expressed
in terms of proximal tubules with vacuolar degeneration and
loss of the brush border.
In order to evaluate the efficiency of the treatment,
administered ad hoc score of damage was applied as follows.
Grade 1. There are up to twenty percent of proximal tubules
with vacuolar degeneration and disruption of the brush
border.
Grade 2. There are between twenty-one and forty percent of
proximal tubules with vacuolar degeneration and disruption
of the brush border.
Grade 3. There are more than forty-one percent of the
proximal tubules with vacuolar degeneration and disruption
of the brush border.
Vacuolar degeneration was defined by the presence of
cytoplasmic vacuoles pushing toward the luminal surface of
the proximal tubular cell, whereas brush border disruption
consisted in a partial or complete loss of its continuity of
solution.
2.4. Preparation of Tissue Extracts. Kidney extracts were
prepared as previously described [25]. Briefly, mice kid-
neys were homogenized at 10% (w/v) in a Potter Elvehjem
homogenizer (Wheaton, NJ, USA) using a homogenization
buffer containing 20mM HEPES, pH 7.9, 1mM MgCl2,
0.5mM EDTA, 1mM EGTA, 1mM dithiothreitol (DTT),
0.5mMphenylmethyl sulphonyl fluoride (PMSF), and 1 ul/ml
PIC. Homogenates were centrifuged at 4000 rpm at 4∘C for
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Table 1: Effects of HD and pyridoxamine administration on mouse body and tissue weight and blood chemistry at 12 weeks of dietary
manipulation. Values are mean ± SEM. ∗𝑝 < 0.05 versus SD; §𝑝 < 0.05 versus HD.
SD SD + P HD HD + P
(𝑛 = 10) (𝑛 = 5) (𝑛 = 10) (𝑛 = 10)
Body weight (g) 25.4 ± 1.3 26.6 ± 3.0 32.8 ± 1.7∗ 34.7 ± 3.6∗
Food intake (g/day) 2.25 ± 0.07 2.72 ± 0.12 2.30 ± 0.28 2.40 ± 0.14
Kidney weight (% BW) 1.02 ± 0.08 1.08 ± 0.11 0.94 ± 0.10 1.11 ± 0.18
Blood glucose (mg/dl) 72.8 ± 18.9 61.8 ± 16.2 138.8 ± 12.7∗ 104.6 ± 9.7∗§
Plasma insulin (𝜇g/l) 85.8 ± 5.3 78.1 ± 12.7 106.8 ± 6.8∗ 103.5 ± 11.0∗
Plasma triglyceride (mg/dl) 37.1 ± 7.6 29.3 ± 5.5 50.5 ± 9.2∗ 34.7 ± 4.7§
Plasma cholesterol (mg/dl) 77.2 ± 6.1 84.8 ± 16.4 97.2 ± 8.2∗ 87.2 ± 2.2
5min and supernatants and pelleted nuclei were separated.
Supernatants were removed and centrifuged at 14,000 rpm at
4∘C for 40min. The supernatants thus obtained, containing
cytosolic proteins, were carefully removed. The pelleted
nuclei were resuspended in extraction buffer containing
20mM HEPES, pH 7.9, 1mM MgCl2, 0.5mM EDTA, 1mM
EGTA, 20% glycerol, 420mM NaCl, 1mM dithiothreitol
(DTT), 0.5mM phenylmethyl sulphonyl fluoride (PMSF),
and 1 ul/ml PIC and centrifuged at 14,000 rpm for 20min
at 4∘C. The amount of protein contained in cytosolic and
nuclear fractions was determined using a BCA protein assay
following the manufacturers’ instructions. Samples were
stored at −80∘C until use.
2.5.Western Blotting. Semiquantitative immunoblot analyses
of nuclear translocation of p65, expression of CML, CEL,
RAGE, vimentin, and fibronectin, and the phosphorylation
of IKK𝛼/𝛽, I𝜅B𝛼, RhoA, MYPT1, and Smad2 were carried
out in mouse kidney tissue extracts. Equal amounts of pro-
teins were separated by SDS-PAGE and electrotransferred to
PVDF membrane. Membranes were incubated with primary
antibodies (rabbit anti-NF-kB [1 : 1000], rabbit anti-IKK𝛼/𝛽
[1 : 1000], rabbit anti-Ser176/180IKK𝛼/𝛽 [1 : 5000], mouse anti-
I𝜅B𝛼 [1 : 1000], mouse anti-Ser32/36I𝜅B𝛼 [1 : 1000], rabbit
anti-RhoA [1 : 1000], rabbit anti-ser188RhoA [1 : 1000], rabbit
anti-MYPT1 [1 : 1000], rabbit anti-Thr853MYPT1 [1 : 1000],
rabbit anti-Smad2 [1 : 1000], rabbit anti-Ser465/467Smad2
[1 : 1000], rabbit anti-Vimentin [1 : 1000] and rabbit anti-
Fibronectin [1 : 5000], goat anti-RAGE, [1 : 1000], mouse anti-
CML [1 : 500], and mouse anti-CEL [1 : 100]) followed by
incubation with appropriated HRP-conjugated secondary
antibodies. Proteins were detected with ECL detection sys-
tem and quantified by densitometry using analytic software
(Quantity-One, Bio-Rad, Hercules, CA, USA). Results were
normalized with respect to densitometric value of tubulin for
cytosolic proteins or histone H3 for nuclear proteins.
2.6. Immunohistochemistry Analysis. RAGE was analyzed by
immunohistochemistry on 4𝜇m formalin-fixed, paraffin-
embedded kidney. Slices were deparaffinized in xylol, rehy-
drated in a graded ethanol series, and subjected to retrieval
(20 minutes, 100∘C, in tris-EDTA buffer solution, pH 9).
Endogenous peroxidase activity was blocked using 0.6%
hydrogen peroxide. After blocking, sections were incubated
overnight with primary antibody (goat anti-RAGE, 1 : 100,
Chemicon International) and subsequently for 1 h with
HRP-conjugated anti-goat secondary antibody. Immuno-
histochemical staining was performed using the Detection
System Peroxidase/DAB. Nuclei were counterstained with
hematoxylin.
2.7. Sirius Red Analysis. Slices were deparaffinized in xylol,
rehydrated in a graded ethanol series, and incubated with a
saturated aqueous solution of picric acid containing Sirius
Red (1mg/ml) for 1 h. After washing twice in acidified water
(containing 0.2% glacial acetic acid), slices were dehydrated
in 100% ethanol and cleared with xylol for microscope
evaluation.
2.8. Statistical Analysis. One-way ANOVA followed by Bon-
ferroni’s post hoc test was adopted for comparison among the
experimental groups. Data were expressed as mean ± SEM.
Statistical tests were performed with GraphPad Prism 6.0
software package (GraphPad Software, San Diego, CA, USA).
Threshold for statistical significance was set to 𝑝 < 0.05.
2.9. Materials. All compounds were purchased from Sigma
Chemical, unless otherwise stated.
3. Results
3.1. Effects of HD and Pyridoxamine Administration on
Metabolic Parameters. Mice fed with the high-fat high-
fructose diet (HD) for 12weeks had greater bodyweights than
control diet-fed littermates (SD) (Table 1). The body weight
gain was not significantly reduced by pyridoxamine. The
levels of fasting blood glucose and insulin were significantly
increased in HD fed mice when compared to SD (Table 1;
𝑝 < 0.05). The concentration of fasting serum glucose, but
not insulin, was significantly reduced by daily administration
of pyridoxamine (HD + P), remaining still higher than
that recorded in the SD group. Chronic exposure to HD
strongly increased serum levels of triglycerides and total
cholesterol. Most notably, pyridoxamine treatment signifi-
cantly normalized the changes in triglycerides contents and
trendily reduced the levels of total cholesterol.
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3.2. Effects of HD and Pyridoxamine Administration on
Kidney Structure and Function. Representative images from
the different experimental groups are shown in Figure 1.
Mice fed with the HD exhibited a severe degree of vacuolar
degeneration, as well as a complete loss of the brush border
integrity. Damage was observed in S1-S2 and S3 parts of
the tubule. Pyridoxamine administration prevented the diet-
induced morphological alterations. Kidneys from groups fed
with chow diet showed proximal tubules with a normal well-
preserved histoarchitecture.
The HD-induced renal pathology correlated with decline
in kidney function, as shown by increased levels of serum
creatinine, which was significantly reduced by pyridoxamine
administration (Figure 2(a)). Similarly, albumin levels were
increased in the HD group compared with the control group
and slightly reduced by pyridoxamine treatment, without
reaching a statistical significance (Figure 2(b)).
3.3. Effects of HD and Pyridoxamine Administration on
Kidney AGEs and RAGE. The causal role of the diet-related
activation of the AGEs-RAGE system in evoking activation of
proinflammatory and profibrotic pathways, thus contributing
to the onset of diet-dependent kidney dysfunction, is well
known. Here we measured local expression levels of the
most known AGEs carboxymethyllysine/carboxyethyllysine
(CML/CEL), showing a massive overproduction at 12 weeks
of dietary manipulation (Figures 3(a) and 3(b)). As expected,
the daily supplementation with the antiglycative pyridox-
amine prevented AGEs accumulation. Immunohistochem-
istry analysis (Figure 4) demonstrated a parallelism between
AGEs overproduction and increased expression of the AGE-
receptor RAGE in kidney sections of HD fed mice. This
evidence was confirmed and quantified by western blot
analysis, showing a threefold increase in RAGE expression
in HD group when compared to SD mice (Figure 3(c)).
Interestingly, both western blot and immunohistochemical
analysis demonstrated that pyridoxamine daily supplemen-
tation prevented renal AGEs accumulation as well as RAGE
hyperexpression.
3.4. Effects ofHDandPyridoxamineAdministration onKidney
NF-kB Pathway Activation. As shown in Figures 5(a) and
5(b), diet manipulation did not affect total expression of IKK
𝛼/𝛽 and I𝜅B𝛼, two core elements of the NF-kB signaling
cascade. As NF-kB activation mainly occurs via IkB kinase-
(IKK-)mediated phosphorylation of the inhibitorymolecule,
IkB𝛼, we measured their levels of phosphorylation showing
that HD evoked increased phosphorylation of IKK 𝛼/𝛽 on
Ser176/180 and of I𝜅B𝛼 on Ser32/36 when compared with mice
under the SD, suggestive of an increased activation of this
pathway.
This overactivation was associated with a marked
increased translocation of the p65 NF-𝜅B subunit from the
cytosol to the nucleus (Figure 5(c)). In contrast, chronic
administration of pyridoxamine to HD fed mice weakened
both IKK 𝛼/𝛽 and I𝜅B𝛼 phosphorylation and counteracted
HD-induced p65 nuclear translocation (Figures 5(a), 5(b),
and 5(c)), thus contributing to reducing local overactivation
of a key proinflammatory pathway.
3.5. Effects of HDand PyridoxamineAdministration onKidney
Fibrosis. As shown in Figure 6(a), a robust increase in the
phosphorylation of SMAD2 was detectable in the kidney of
HDmice. SMAD2 is the canonical profibrotic transcriptional
factor that contributes to transmitting TGF-𝛽 signals from
cell surface to the nucleus promoting the production of
profibrotic proteins such as vimentin and fibronectin. As
expected, the increased activation of SMAD2 was associated
with a higher expression of vimentin and fibronectin (Figures
6(b) and 6(c)).
Most notably, pyridoxamine supply significantly reduced
the activity of the profibrotic pathway by halving the phos-
phorylation of SMAD2 as well as the following expression of
vimentin and fibronectin.
TGF-𝛽 also activates the noncanonical pathway of RhoA,
a member of the Ras superfamily of small GTP-binding
proteins, which contributes to fibronectin production in
diabetic kidney.
Here we demonstrated that the intensity of RhoA phos-
phorylation in Ser188 was halved in the kidneys of hyper-
calorically fed mice when compared to chow fed mice
(Figure 7(a)), thus indicating a diet-dependent massive
increase of RhoA pathway activity. This effect was associated
with a significant increase of the Ser853 phosphorylation
of MYPT1 (a downstream marker of RhoA/ROCK path-
way) (Figure 7(b)). In contrast, treatment of mice exposed
to HD with pyridoxamine abolished all the alterations in
RhoA/ROCK pathway evoked by HD.
However, as shown in Figure 8, no significant difference
in the collagen deposition was detectable with Sirius Red
assay among the experimental groups, thus demonstrating
that a marked fibrotic process was not yet fully developed at
12 weeks of dietary manipulation.
4. Discussion
In keeping with previously published papers [24, 26], we
confirmed that 12 weeks of dietary manipulation with a
high-fat high-fructose diet evoked metabolic derangements,
leading to kidney injury, as shown here by alteration in tissue
morphology and reduction in its functionality (increased
serumcreatinine and albuminuria).Most notably, we demon-
strated that oral chronic administration of pyridoxamine,
a structural analog of vitamin B6 that exerts antiglycative
effect, at the dose of 150mg/kg/die, significantly reduced the
metabolic alterations by improving fasting glycaemia and
lipid profile. These beneficial effects were associated with
improvement in kidney function and morphology due, at
least in part, to significant reduction in the local accumula-
tion of CEL and CML (the two most studied AGEs).
In fact, the key role of AGEs accumulation and/or
RAGE overexpression in the development of glomerular
kidney injury has been recently documented by Yasuhiko
and colleagues using transgenic mice overexpressing RAGE
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Figure 1: Effects of HD and pyridoxamine administration on kidney structure. (a) Representative kidney section from the experimental
group stained with PAS (20x) and (b) score quantification. SD with or without pyridoxamine treatment (150mg/kg/day): proximal tubules
with a normal histoarchitecture. HD: severe degree of tubular vacuolar degeneration and loss of the brush border. HD + pyridox: proximal
tubules with almost full protected histology. Values are mean ± SEM of five animals per group. ∗𝑝 < 0.05 versus SD; §𝑝 < 0.05 versus HD.
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Figure 2: Effects of HD and pyridoxamine administration on kidney function. Serum creatinine (a) and urinary albumin (b) levels were
measured in mice exposed to SD or HD in the absence or presence of pyridoxamine (150mg/kg/day). Values are mean ± SEM of five-ten
animals per group. ∗𝑝 < 0.05 versus SD; §𝑝 < 0.05 versus HD.
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Figure 3: Effects of HD and pyridoxamine administration on kidney AGE and RAGE expression. CEL (a), CML (b), and RAGE (c) were
analyzed by western blot on kidney homogenates obtained from mice exposed to SD or HD with or without pyridoxamine administration
(150mg/kg/day). Protein expression is measured as relative optical density (OD), corrected for the corresponding tubulin contents and
normalized to the SD band. The data are means ± SEM, five animals per group. ∗𝑝 < 0.05 versus SD; §𝑝 < 0.05 versus HD.
in vascular cells. As shown by the authors, RAGE overex-
pression led to renal dysfunction and advanced glomeru-
losclerosis and its selective inhibition reverted the renal
deleterious effects [27]. Very recently, the involvement of
AGEs accumulation in tubular injury and the protective
effects of anti-RAGE antibody to block CML-RAGE pathway
has been demonstrated in human renal tubular epithelial
cell line [28]. According to these findings, the antiglycative
compound pyridoxamine has been recently suggested as
effective supplementary approach in patients with initial
diabetic nephropathy impairment [4, 6]. However, so far, the
molecular mechanism(s) underlying its protective role has
been slightly examined.
Here we investigated the effects of pyridoxamine on the
AGEs/RAGE signaling pathway and the following signaling
cascades, focusing on the NF-kB inflammatory signaling
pathway. AGEs/RAGE interaction, indeed, stimulates the
activation of NF-𝜅B, a key transcriptional factor which
connects immune response to infection and inflammation.
In its inactive form, NF-𝜅B is sequestered by the inhibitor
of 𝜅B (I𝜅B) in the cytoplasm and this can be released
upon phosphorylation by I𝜅B kinase complex (IKK), which
is formed by three subunits termed as IKK𝛼, 𝛽, and 𝛾.
Once translocated in the nucleus, NF-𝜅B binds to RAGE
promoter and further enhances RAGE expression. Thus,
the activation of RAGE by AGEs induces RAGE expres-
sion [29]. Moreover, NF-kB activation contributes to renal
inflammation mostly by upregulating the renal expression
of chemokines and cytokines involved in the increasing of
vascular permeability such as monocyte chemoattractant
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Figure 4: Effects of HD and pyridoxamine administration on kidney RAGE expression. Representative 20x and 40x magnification images
of immunohistochemistry analysis for RAGE on kidney sections from mice fed with the SD or the HD, with or without pyridoxamine
administration (150mg/kg/day).
protein-1 (MCP-1), IL- (interleukin-) 1, IL-6, IL-18, and
TNF (tumour necrosis factor), which are critically involved
in kidney disease pathogenesis [19]. Finally, stimulation of
RAGE by AGEs increases ROS levels through activation of
NAPDH oxidase [30] enhancing levels of oxidative stress and
consequently further contributing to an excessive inflamma-
tory response. Our data strongly support the key role of this
signaling pathway in the pathogenesis of diet-related kidney
dysfunction and the crucial cross-talk mechanism between
AGE-RAGE and NF-kB cascades, showing a parallelism
between the AGE accumulation/RAGE overexpression and
the robust activation and translocation of p65 subunit of
NF-kB from the cytosol to the nucleus following dietary
manipulation. Interestingly, both the cascades were blunted
in their activation by pyridoxamine administration.
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Figure 5: Effects ofHD and pyridoxamine administration on kidneyNF-kB pathway activation. Total protein expressions of IKK (a) and IkB𝛼
(b) and their related phosphorylated forms and NF-kB p65 subunit translocation in the nucleus (c) were analyzed by western blot on kidney
homogenates obtained from mice exposed to SD or HD, with or without pyridoxamine administration (150mg/kg/day). Protein expression
is measured as relative optical density (OD), corrected for the corresponding tubulin or histone H3 contents and normalized to the SD band.
Results are shown as phosphorylated/total protein ratio (a and b) or as nucleus/cytosol protein ratio (c). The data are means ± SEM of three
separate experiments, five animals per group. ∗𝑝 < 0.05 versus SD; §𝑝 < 0.05 versus HD.
Recent findings convincingly showed that the activation
of the proinflammatory NF-kB pathway is also involved
in the induction of expression and/or activity of selective
profibrogenic signaling pathways, including the prosclerotic
cytokine TGF-𝛽 (transforming growth factor-𝛽) [19]. Old-
field and others [31] demonstrated that the activation of
RAGE induced the overexpression of TGF-𝛽, thus demon-
strating the involvement of AGEs in the onset of tubulointer-
stitial fibrosis. Previously published in vitro studies demon-
strated that AGEs may evoke production and accumulation
of collagen [32, 33].
Unfortunately, we could not confirm these findings, as
our model of mild renal injury does not allow the detection
of significant accumulation of extracellular collagen. Longer
kinetics of dietary manipulation and/or more severe dietary
insult would be requested to confirm in vivo these findings.
However, our main focus was the study of the molecular
mechanisms of protection evoked by pyridoxamine, which
should be clinically used as supplementary approach to delay
the development of diabetic nephropathy and not to counter-
act a drastic deposition of collagen and renal fibrosis. Thus,
we decided to deepen our investigation on potential pharma-
cological modulation of the two most widely known TGF-
𝛽 depending early profibrotic pathways, whose correlation
with AGEs accumulation and pyridoxamine administration
has not yet been tested and was not even proposed.
The first cascade is the canonical signaling pathway that
involves the phosphorylation and activation of Smad2 and
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Figure 6: Effects of HD and pyridoxamine administration on profibrotic response. SMAD2 phosphorylation (a) and total protein expression
of fibronectin (b) and vimentin (c) were analyzed by western blot on kidney homogenates obtained from mice exposed to SD or HD, with
or without pyridoxamine administration (150mg/kg/day). Protein expression is measured as relative optical density (OD), corrected for the
corresponding total SMAD or tubulin contents and normalized to the SD band.The data are means ± SEM, five animals per group. ∗𝑝 < 0.05
versus SD; §𝑝 < 0.05 versus HD.
Smad3. Smad4 then binds activated Smad2/3, which enables
this complex to translocate to the nucleus and transcribe spe-
cific profibrotic genes such as fibronectin and vimentin [34].
Recent studies identified within the inflammation/fibrosis
pathway SMAD2/3 an essential modulator of insulin sensi-
tivity related to glomerular dysfunction. Specifically, Smad
signaling has an essential role in the development and
progression of HFD-induced kidney injury and progres-
sion of obesity-related glomerulopathy. Inhibition of Smad
signaling, indeed, protects podocytes from metabolic stress
through increasing mitochondrial activities [35].
The second cascade is the RhoA/ROCK pathway. RhoA
is a member of the Ras superfamily of small GTP-binding
proteins, which has been demonstrated to contribute to
profibrotic signaling and fibronectin production in diabetic
kidney and interfering with VEGF-mediated endothelial cell
function [36–38].
Here we demonstrated, for the first time, that both
the canonical and noncanonical profibrotic pathways are
affected by pharmacological modulation of local AGEs accu-
mulation. In fact, pyridoxamine administration resulted in
robust reduction of the enhanced phosphorylation and thus
activation of Smad2 and the overexpression of vimentin and
fibronectin, two important profibrotic proteins upregulated
by Smad2 pathway activation. At the same time, pyridox-
amine treatment significantly reverted the activation of the
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Figure 7: Effects ofHD and pyridoxamine administration on kidney RhoApathway activation. Total protein expressions of RhoA (a),MYPT1
(b), and their related phosphorylated forms were analyzed by western blot on kidney homogenates obtained frommice exposed to SD or HD,
with or without pyridoxamine administration (150mg/kg/day). Protein expression is measured as relative optical density (OD), corrected for
the corresponding total protein contents and normalized to the SD band.The data are means ± SEM, five animals per group. ∗𝑝 < 0.05 versus
SD; §𝑝 < 0.05 versus HD.
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Figure 8: Effects of HD and pyridoxamine administration on kidney fibrosis. Representative kidney section from the experimental group
stained with Sirius Red (20x).
RhoA pathway and the following phosphorylation ofMYPT1,
a RhoA downstream effector.
These modulatory effects of pyridoxamine on the two
fibrotic cascades can be consequences of the reduction of the
NF-kB pathway activation due to pyridoxamine interference
with the AGEs/RAGE and NF-kB cross-talk mechanism.
However, we cannot rule out direct interaction between
AGEs and the RhoA/ROCK pathway. In fact, AGEs have
been recently demonstrated to directly activate RhoA in
endothelial cells, leading to increased hyperpermeability,
BioMed Research International 11
through a selective complex formation between RAGE and
RhoA [39]. Further investigations are needed to better clarify
the involvement of NF-kB independent mechanisms of acti-
vation of profibrotic pathways by AGEs.
To the best of our knowledge, this is the first study that
analyzes from a mechanistic point of view the consequences
of pyridoxamine chronic oral administration in a model of
diet-induced kidney dysfunction, demonstrating that this
antiglycative compound exerts protective beneficial nephrol-
ogy effects by reducing AGEs levels, leading to interferences
with selective inflammatory and profibrotic signaling path-
ways.
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